A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 15, 2021

Primary Completion Date

December 17, 2023

Study Completion Date

May 13, 2026

Conditions
Carcinoma, Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

nivolumab

Specified dose on Specified days

BIOLOGICAL

ipilimumab

Specified dose on Specified days

DRUG

cabozantinib

Specified dose on Specified days

BIOLOGICAL

docetaxel

Specified dose on Specified days

BIOLOGICAL

ramucirumab

Specified dose on Specified days

DRUG

lucitanib

Specified dose on Specified days

Trial Locations (23)

1426

Local Institution, Ciudad Autónoma de Buenos Aires

1430

Local Institution, Caba

1431

Local Institution, Buenos Aires

2100

Local Institution, Copenhagen Ø

3000

Local Institution, Leuven

6000

Local Institution, Charleroi

6060

Local Institution, Gilly

11527

Local Institution, Athens

18547

Local Institution, Neo Faliro

27010

Local Institution, Torreón

44280

Local Institution, Zapopan

48201

Local Institution, Detroit

72530

Local Institution, Puebla City

200347

Local Institution, Craiova

300696

Local Institution, Timișoara

C1199ABB

Local Institution, Buenos Aires

C1280

Local Institution, Capital

03240

Local Institution, Mexico City

1066 CX

Local Institution, Amsterdam

3015 GD

Local Institution, Rotterdam

0379

Local Institution, Oslo

02-781

Local Institution, Warsaw

30-688

Local Institution, Krakow

Sponsors
All Listed Sponsors
collaborator

Clovis Oncology, Inc.

INDUSTRY

collaborator

Exelixis

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY